{ "run": { "id": "cmnr14z6i0605p658zdew235u", "region": "US", "assetId": "cmnr14z6205zzp65876d2fyvt", "ticker": "RMD", "snapshotId": "cmnr14z6b0601p658d7f0liip", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:42.424Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14z6b0601p658d7f0liip", "assetId": "cmnr14z6205zzp65876d2fyvt", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 231.3, "price": 230.7, "dayLow": 229.82, "volume": 1116521, "dayHigh": 234.905, "currency": "USD", "prevClose": 226.05, "week52Low": 199.92, "week52High": 293.81 }, "fundamentals": { "pe": 27.0157068062827, "beta": 0.815999786912518, "epsTTM": 9.55, "fcfTTM": 1550350000, "growth": { "epsYoy": 0.3760806916426513, "revenueYoy": -0.7235294220518829 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": 0.2759283051543145, "gross": 0.617598439142878, "operating": 0.3455561115765444 }, "website": "http://resmed.com", "industry": "Medical", "pegRatio": 0.71834867906361, "ebitdaTTM": 1813209000, "forwardPe": 23.7569060773481, "marketCap": 33419694564, "totalCash": 1417069000, "totalDebt": 663829000, "debtEquity": 0.111981868204326, "quickRatio": 1.925066941000582, "revenueTTM": 1422808000, "companyName": "RESMED INC", "priceToBook": 6.34276513570445, "currentRatio": 3.059657210799655, "dividendYield": 0.00821288230533873, "returnOnAssets": 0.04616910707166688, "returnOnEquity": 0.23471114180144, "analystOpinions": null, "businessSummary": "ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers (i.e. home health, hospice, skilled nursing facilities, life plan communities, senior living centers, and private duty).", "enterpriseValue": 37311570000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 10600, "sharesOutstanding": 145678401, "enterpriseToEbitda": 20.57764438627869, "analystTargetMedian": null, "enterpriseToRevenue": 26.2238966888013, "operatingCashflowTTM": 797066000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:42.420Z" }, "results": [ { "id": "cmnr14z6l0609p65838sjar0h", "runId": "cmnr14z6i0605p658zdew235u", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"RMD\",\"currency\":\"USD\",\"current_price\":230.7,\"target_price_6m\":248,\"target_price_12m\":265,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Core sleep/respiratory device franchise shows durable double-digit earnings growth\",\"Post-divestiture focus sharpens capital allocation on high-margin medical devices\",\"PEG ratio of 0.72 suggests market undervalues forward earnings trajectory\",\"Strong balance sheet with net cash enables buybacks and dividend growth\",\"GLP-1 overhang risk has moderated but remains a valuation cap near-term\"],\"key_drivers\":[{\"driver\":\"CPAP/mask installed base growth and cloud-connected recurring revenue\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Gross margin expansion from mix shift toward higher-margin masks\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug adoption potentially reducing addressable sleep apnea market\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Post-divestiture revenue base reset lowers top-line but lifts margins\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"International market penetration especially in Europe and Asia-Pacific\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Competitive threat from Philips re-entry into CPAP market\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($1.55B TTM) supporting capital returns\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Potential tariff/supply chain disruptions on device manufacturing\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"GLP-1 drugs prove more effective for OSA, reducing CPAP demand materially\",\"Philips Respironics regains significant share after recall recovery\",\"Regulatory changes or reimbursement cuts pressure device pricing\",\"Macroeconomic slowdown delays elective sleep study referrals\",\"Valuation premium compresses if growth decelerates below expectations\"],\"assumptions\":{\"revenue_cagr_3y\":0.09,\"ebit_margin_target\":0.36,\"wacc\":0.085,\"terminal_multiple\":24},\"scenarios\":{\"bear\":{\"target_price\":195,\"prob\":0.2,\"notes\":\"GLP-1 fears re-escalate, multiple compresses to ~20x forward earnings.\"},\"base\":{\"target_price\":265,\"prob\":0.55,\"notes\":\"Steady EPS growth to ~$10.80, market sustains ~24.5x forward P/E.\"},\"bull\":{\"target_price\":310,\"prob\":0.25,\"notes\":\"Accelerating device adoption, margin upside drives EPS above $11.50, re-rate to ~27x.\"}},\"method_notes\":\"Blended earnings-power and FCF valuation. Core EPS projected to grow ~12% on device volume/mix and margin expansion. Revenue TTM appears post-divestiture (~$1.4B vs prior ~$4.7B); EPS growth unaffected. Forward P/E of 23.8x vs PEG 0.72 suggests moderate undervaluation. 12M target implies ~15% return, consistent with BUY. GLP-1 risk moderates conviction to 0.65. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "GLP-1 drugs prove more effective for OSA, reducing CPAP demand materially", "Philips Respironics regains significant share after recall recovery", "Regulatory changes or reimbursement cuts pressure device pricing", "Macroeconomic slowdown delays elective sleep study referrals", "Valuation premium compresses if growth decelerates below expectations" ], "ticker": "RMD", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady EPS growth to ~$10.80, market sustains ~24.5x forward P/E.", "target_price": 265 }, "bear": { "prob": 0.2, "notes": "GLP-1 fears re-escalate, multiple compresses to ~20x forward earnings.", "target_price": 195 }, "bull": { "prob": 0.25, "notes": "Accelerating device adoption, margin upside drives EPS above $11.50, re-rate to ~27x.", "target_price": 310 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.09, "terminal_multiple": 24, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "CPAP/mask installed base growth and cloud-connected recurring revenue", "impact": "HIGH", "direction": "POS" }, { "driver": "Gross margin expansion from mix shift toward higher-margin masks", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug adoption potentially reducing addressable sleep apnea market", "impact": "MED", "direction": "NEG" }, { "driver": "Post-divestiture revenue base reset lowers top-line but lifts margins", "impact": "MED", "direction": "POS" }, { "driver": "International market penetration especially in Europe and Asia-Pacific", "impact": "MED", "direction": "POS" }, { "driver": "Competitive threat from Philips re-entry into CPAP market", "impact": "MED", "direction": "NEG" }, { "driver": "Strong FCF generation ($1.55B TTM) supporting capital returns", "impact": "HIGH", "direction": "POS" }, { "driver": "Potential tariff/supply chain disruptions on device manufacturing", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended earnings-power and FCF valuation. Core EPS projected to grow ~12% on device volume/mix and margin expansion. Revenue TTM appears post-divestiture (~$1.4B vs prior ~$4.7B); EPS growth unaffected. Forward P/E of 23.8x vs PEG 0.72 suggests moderate undervaluation. 12M target implies ~15% return, consistent with BUY. GLP-1 risk moderates conviction to 0.65. Not investment advice.", "current_price": 230.7, "recommendation": "BUY", "thesis_bullets": [ "Core sleep/respiratory device franchise shows durable double-digit earnings growth", "Post-divestiture focus sharpens capital allocation on high-margin medical devices", "PEG ratio of 0.72 suggests market undervalues forward earnings trajectory", "Strong balance sheet with net cash enables buybacks and dividend growth", "GLP-1 overhang risk has moderated but remains a valuation cap near-term" ], "target_price_6m": 248, "target_price_12m": 265 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 42457, "createdAt": "2026-04-09T05:21:42.424Z", "usage": { "inputTokens": 3674, "outputTokens": 1606, "costUsd": 0.05852 } }, { "id": "cmnr14z6l060cp6589ve6m6s9", "runId": "cmnr14z6i0605p658zdew235u", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF-Based Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"RMD\",\n \"currency\": \"USD\",\n \"current_price\": 230.7,\n \"target_price_6m\": 240,\n \"target_price_12m\": 252,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Strong market leader in sleep apnea treatment.\",\n \"High profitability with robust margins.\",\n \"Earnings growth despite recent revenue decline.\",\n \"Long-term demographic tailwinds support growth.\",\n \"Valuation offers moderate upside potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Aging population increasing demand\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Technological innovation in devices\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive intensity in medical sector\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory approval processes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic sensitivity of healthcare\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Global expansion opportunities\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Operational efficiency improvements\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Strong balance sheet with low debt\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Volatility in revenue growth rates\",\n \"Regulatory changes in key markets\",\n \"Technological obsolescence risk\",\n \"Macroeconomic downturns affecting spending\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.08,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 210, \"prob\": 0.2, \"notes\": \"Lower growth and multiple contraction.\" },\n \"base\": { \"target_price\": 252, \"prob\": 0.6, \"notes\": \"Base case with moderate growth assumptions.\" },\n \"bull\": { \"target_price\": 280, \"prob\": 0.2, \"notes\": \"Higher adoption and margin expansion.\" }\n },\n \"method_notes\": \"DCF valuation with 6% revenue CAGR, 35% EBIT margin, 8% WACC, 20x terminal multiple. BUY due to 9% expected upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "DCF-Based Equity Research Model", "risks": [ "Volatility in revenue growth rates", "Regulatory changes in key markets", "Technological obsolescence risk", "Macroeconomic downturns affecting spending" ], "ticker": "RMD", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Base case with moderate growth assumptions.", "target_price": 252 }, "bear": { "prob": 0.2, "notes": "Lower growth and multiple contraction.", "target_price": 210 }, "bull": { "prob": 0.2, "notes": "Higher adoption and margin expansion.", "target_price": 280 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.06, "terminal_multiple": 20, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "Aging population increasing demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Technological innovation in devices", "impact": "MED", "direction": "POS" }, { "driver": "Competitive intensity in medical sector", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approval processes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic sensitivity of healthcare", "impact": "LOW", "direction": "NEG" }, { "driver": "Global expansion opportunities", "impact": "MED", "direction": "POS" }, { "driver": "Operational efficiency improvements", "impact": "MED", "direction": "POS" }, { "driver": "Strong balance sheet with low debt", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF valuation with 6% revenue CAGR, 35% EBIT margin, 8% WACC, 20x terminal multiple. BUY due to 9% expected upside. Not investment advice.", "current_price": 230.7, "recommendation": "BUY", "thesis_bullets": [ "Strong market leader in sleep apnea treatment.", "High profitability with robust margins.", "Earnings growth despite recent revenue decline.", "Long-term demographic tailwinds support growth.", "Valuation offers moderate upside potential." ], "target_price_6m": 240, "target_price_12m": 252 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 345, "createdAt": "2026-04-09T05:21:42.424Z", "usage": { "inputTokens": 2174, "outputTokens": 3826, "costUsd": 0.002216 } }, { "id": "cmnr14z6l060ap658fszmk77n", "runId": "cmnr14z6i0605p658zdew235u", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_RMD\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"RMD\",\n \"currency\": \"USD\",\n \"current_price\": 230.7,\n \"target_price_6m\": 245.0,\n \"target_price_12m\": 265.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Dominant market share in sleep apnea devices following the extended Philips Respironics recall.\",\n \"High-margin SaaS business provides recurring revenue and strong ecosystem stickiness.\",\n \"GLP-1 weight loss drug fears are overblown; CPAP remains the gold standard treatment.\",\n \"Strong balance sheet with low debt enables strategic M&A and share buybacks.\",\n \"Valuation is reasonable at ~24x forward P/E given expected double-digit EPS growth.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Philips recall duration\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 drug adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"SaaS segment growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Gross margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply chain stability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New mask product launches\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Widespread adoption of GLP-1 drugs significantly reducing obesity-related sleep apnea TAM.\",\n \"Philips re-entering the market with aggressive pricing to win back lost share.\",\n \"Supply chain constraints impacting device manufacturing and gross margins.\",\n \"Data privacy breaches in cloud-connected devices leading to regulatory fines.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.085,\n \"terminal_multiple\": 22.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 190.0,\n \"prob\": 0.2,\n \"notes\": \"GLP-1 drugs significantly reduce sleep apnea TAM and Philips aggressively regains market share.\"\n },\n \"base\": {\n \"target_price\": 265.0,\n \"prob\": 0.6,\n \"notes\": \"Steady CPAP market share gains and SaaS growth offset minor GLP-1 headwinds.\"\n },\n \"bull\": {\n \"target_price\": 300.0,\n \"prob\": 0.2,\n \"notes\": \"Philips recall extends indefinitely and software SaaS margins expand significantly.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 25x forward P/E and DCF (8.5% WACC, 22x terminal multiple). Snapshot revenue anomaly noted; normalized growth assumed for targets. Expected return is ~14.8%, supporting a BUY rating. This is not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch_RMD", "risks": [ "Widespread adoption of GLP-1 drugs significantly reducing obesity-related sleep apnea TAM.", "Philips re-entering the market with aggressive pricing to win back lost share.", "Supply chain constraints impacting device manufacturing and gross margins.", "Data privacy breaches in cloud-connected devices leading to regulatory fines." ], "ticker": "RMD", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady CPAP market share gains and SaaS growth offset minor GLP-1 headwinds.", "target_price": 265 }, "bear": { "prob": 0.2, "notes": "GLP-1 drugs significantly reduce sleep apnea TAM and Philips aggressively regains market share.", "target_price": 190 }, "bull": { "prob": 0.2, "notes": "Philips recall extends indefinitely and software SaaS margins expand significantly.", "target_price": 300 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.08, "terminal_multiple": 22, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "Philips recall duration", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug adoption", "impact": "HIGH", "direction": "NEG" }, { "driver": "SaaS segment growth", "impact": "MED", "direction": "POS" }, { "driver": "Gross margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Supply chain stability", "impact": "MED", "direction": "POS" }, { "driver": "New mask product launches", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 25x forward P/E and DCF (8.5% WACC, 22x terminal multiple). Snapshot revenue anomaly noted; normalized growth assumed for targets. Expected return is ~14.8%, supporting a BUY rating. This is not investment advice.", "current_price": 230.7, "recommendation": "BUY", "thesis_bullets": [ "Dominant market share in sleep apnea devices following the extended Philips Respironics recall.", "High-margin SaaS business provides recurring revenue and strong ecosystem stickiness.", "GLP-1 weight loss drug fears are overblown; CPAP remains the gold standard treatment.", "Strong balance sheet with low debt enables strategic M&A and share buybacks.", "Valuation is reasonable at ~24x forward P/E given expected double-digit EPS growth." ], "target_price_6m": 245, "target_price_12m": 265 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 22695, "createdAt": "2026-04-09T05:21:42.424Z", "usage": { "inputTokens": 2539, "outputTokens": 846, "costUsd": 0.01523 } }, { "id": "cmnr14z6l0608p658y02y6pvm", "runId": "cmnr14z6i0605p658zdew235u", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"RMD\",\"currency\":\"USD\",\"current_price\":230.7,\"target_price_6m\":242,\"target_price_12m\":252,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Core sleep-apnea franchise supports recurring high-margin mask and accessories revenue.\",\"Digital care software broadens moat and diversifies beyond devices.\",\"Margins and cash generation remain strong, with net cash balance sheet.\",\"Valuation has reset from highs, but still prices in durable growth.\",\"GLP-1 demand uncertainty and payer competition cap upside near term.\"],\"key_drivers\":[{\"driver\":\"Sleep apnea diagnosis growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Mask resupply cadence\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Homecare software adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin mix and manufacturing efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net cash capital flexibility\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 impact on CPAP demand\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pricing and reimbursement pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Execution in software integration\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Faster-than-expected GLP-1 substitution effect\",\"Reimbursement or competitive pricing pressure\",\"Software segment execution missteps\",\"Supply chain or regulatory disruptions\"],\"assumptions\":{\"revenue_cagr_3y\":0.095,\"ebit_margin_target\":0.335,\"wacc\":0.085,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":205,\"prob\":0.25,\"notes\":\"Demand softens and multiples compress on GLP-1 concerns.\"},\"base\":{\"target_price\":252,\"prob\":0.5,\"notes\":\"Steady device growth and software expansion support modest rerating.\"},\"bull\":{\"target_price\":290,\"prob\":0.25,\"notes\":\"Replacement demand stays strong and margins outperform expectations.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA using assumed mid-teens EPS growth and ~33.5% EBIT margin. Snapshot quote fields kept exact; snapshot revenue/growth appear inconsistent with company scale, so growth was treated cautiously as assumptions. Base-case 12M upside ~9% supports BUY; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation v2", "risks": [ "Faster-than-expected GLP-1 substitution effect", "Reimbursement or competitive pricing pressure", "Software segment execution missteps", "Supply chain or regulatory disruptions" ], "ticker": "RMD", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady device growth and software expansion support modest rerating.", "target_price": 252 }, "bear": { "prob": 0.25, "notes": "Demand softens and multiples compress on GLP-1 concerns.", "target_price": 205 }, "bull": { "prob": 0.25, "notes": "Replacement demand stays strong and margins outperform expectations.", "target_price": 290 } }, "confidence": 0.64, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.095, "terminal_multiple": 22, "ebit_margin_target": 0.335 }, "key_drivers": [ { "driver": "Sleep apnea diagnosis growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Mask resupply cadence", "impact": "HIGH", "direction": "POS" }, { "driver": "Homecare software adoption", "impact": "MED", "direction": "POS" }, { "driver": "Margin mix and manufacturing efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Net cash capital flexibility", "impact": "LOW", "direction": "POS" }, { "driver": "GLP-1 impact on CPAP demand", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pricing and reimbursement pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Execution in software integration", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended forward P/E and EV/EBITDA using assumed mid-teens EPS growth and ~33.5% EBIT margin. Snapshot quote fields kept exact; snapshot revenue/growth appear inconsistent with company scale, so growth was treated cautiously as assumptions. Base-case 12M upside ~9% supports BUY; not investment advice.", "current_price": 230.7, "recommendation": "BUY", "thesis_bullets": [ "Core sleep-apnea franchise supports recurring high-margin mask and accessories revenue.", "Digital care software broadens moat and diversifies beyond devices.", "Margins and cash generation remain strong, with net cash balance sheet.", "Valuation has reset from highs, but still prices in durable growth.", "GLP-1 demand uncertainty and payer competition cap upside near term." ], "target_price_6m": 242, "target_price_12m": 252 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0d2256c2076937cc0069d75cf60fd08195b4cecf9a0bb9a7c1", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 31009, "createdAt": "2026-04-09T05:21:42.424Z", "usage": { "inputTokens": 2448, "outputTokens": 1776, "costUsd": 0.029148 } }, { "id": "cmnr14z6l060bp658p6staf3r", "runId": "cmnr14z6i0605p658zdew235u", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Integrated DCF Scenario Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"RMD\",\n \"currency\": \"USD\",\n \"current_price\": 230.7,\n \"target_price_6m\": 248,\n \"target_price_12m\": 265,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Dominant in CPAP market with over 60% gross margins.\",\n \"Recurring accessory revenue ensures high cash flow visibility.\",\n \"Strong 38% EPS growth despite sharp revenue decline.\",\n \"Aging population drives long-term demand for respiratory devices.\",\n \"Elevated 27x PE and competition limit valuation upside.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Rising OSA awareness and diagnosis rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Recurring revenue from masks and supplies\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product innovation in connected devices\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"International market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Intense competition in sleep therapy\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Healthcare reimbursement policy shifts\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"High current EV/revenue multiple\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Consistent free cash flow generation\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Intensifying competitive landscape\",\n \"Adverse reimbursement policy changes\",\n \"Supply chain disruptions\",\n \"Regulatory delays for new products\",\n \"Impact of revenue volatility on margins\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.085,\n \"ebit_margin_target\": 0.36,\n \"wacc\": 0.085,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 195,\n \"prob\": 0.25,\n \"notes\": \"Prolonged revenue weakness and margin pressure from competition.\"\n },\n \"base\": {\n \"target_price\": 265,\n \"prob\": 0.5,\n \"notes\": \"Moderate recovery and growth from core sleep therapy.\"\n },\n \"bull\": {\n \"target_price\": 315,\n \"prob\": 0.25,\n \"notes\": \"Strong adoption of new devices and software solutions.\"\n }\n },\n \"method_notes\": \"DCF using 8.5% 3Y revenue CAGR, 36% EBIT margin, 8.5% WACC, 20x terminal. 15% implied upside supports BUY despite mixed rev/EPS trends. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Integrated DCF Scenario Model", "risks": [ "Intensifying competitive landscape", "Adverse reimbursement policy changes", "Supply chain disruptions", "Regulatory delays for new products", "Impact of revenue volatility on margins" ], "ticker": "RMD", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate recovery and growth from core sleep therapy.", "target_price": 265 }, "bear": { "prob": 0.25, "notes": "Prolonged revenue weakness and margin pressure from competition.", "target_price": 195 }, "bull": { "prob": 0.25, "notes": "Strong adoption of new devices and software solutions.", "target_price": 315 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.085, "terminal_multiple": 20, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "Rising OSA awareness and diagnosis rates", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring revenue from masks and supplies", "impact": "HIGH", "direction": "POS" }, { "driver": "Product innovation in connected devices", "impact": "MED", "direction": "POS" }, { "driver": "International market expansion", "impact": "MED", "direction": "POS" }, { "driver": "Intense competition in sleep therapy", "impact": "HIGH", "direction": "NEG" }, { "driver": "Healthcare reimbursement policy shifts", "impact": "HIGH", "direction": "NEG" }, { "driver": "High current EV/revenue multiple", "impact": "MED", "direction": "NEG" }, { "driver": "Consistent free cash flow generation", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 8.5% 3Y revenue CAGR, 36% EBIT margin, 8.5% WACC, 20x terminal. 15% implied upside supports BUY despite mixed rev/EPS trends. not investment advice.", "current_price": 230.7, "recommendation": "BUY", "thesis_bullets": [ "Dominant in CPAP market with over 60% gross margins.", "Recurring accessory revenue ensures high cash flow visibility.", "Strong 38% EPS growth despite sharp revenue decline.", "Aging population drives long-term demand for respiratory devices.", "Elevated 27x PE and competition limit valuation upside." ], "target_price_6m": 248, "target_price_12m": 265 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "9ffeff3e-5a93-9dc3-80a6-7a0f603c6df8", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 21465, "createdAt": "2026-04-09T05:21:42.424Z", "usage": { "inputTokens": 2785, "outputTokens": 4293, "costUsd": 0.07275 } } ] } }